International Clinical Trial: A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07816198) titled 'A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy' on Sept. 7.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).

Primary Sponsor: Addpharma Inc.

Condition: Type 2 Diabetes Mellitus (T2DM)

Intervention: Drug: AD-233A Drug: AD-233B Drug: AD-233C Drug: AD-233D Drug: AD-233A Placebo

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: September 30, 2026

Target Sample Size: 354

To know more, visit ht...